hrp0097p2-278 | Late Breaking | ESPE2023

Endocrine dysfunction in Charge Syndrome – short case series

Costa Cristiana , Laura Fitas Ana , Diamantino Catarina , Lopes Patrícia , Limbert Catarina , Lopes Lurdes

Introduction: CHARGE syndrome is a rare constellation of congenital malformations caused by mutations in CHD7 gene. The acronym stands for coloboma, heart defect, choanal atresia, retarded growth and development, genital hypoplasia, ear abnormalities, and/or hearing loss. Endocrine disorders associated with this syndrome include hypogonadotropic hypogonadism, ...

hrp0086p2-p774 | Pituitary and Neuroendocrinology P2 | ESPE2016

Insulin Sensitivity in Girls with Central Precocious Puberty at Diagnosis and at 6 Months of GnRH Analogue Treatment

Arcari Andrea , Freire Analia , Escobar Maria Eugenia , Ballerini Maria Gabriela , Ropelato Maria Gabriela , Bergada Ignacio , Gryngarten Mirta

Background: Puberty is associated with a physiological decline in insulin sensitivity. Overweight and obesity are common among girls with Central Precocious Puberty (CPP). CPP and early menarche have been considered as risk factors for obesity and cardiovascular diseases during adulthood. Besides, concern has been raised by the potential impact of GnRH analogues (GnRH-a) treatment on body weight and metabolic profile.Objective and hypotheses: To evaluate...

hrp0082p2-d3-342 | Diabetes (2) | ESPE2014

Prolonged Treatment with Vitamin D Supplementation and High Dose is Necessary to Treat Vitamin D Deficiency/Insufficiency (VDD/I) in Children and Adolescents with Type 1 Diabetes

Xatzipsalti Maria , Dolianiti Maria , Papadopoulou Konstantina , Kouloufakou Penelope , Mitravela Vasiliki-Ioanna , Dracopoulou Maria , Stamogiannou Lela , Vazeou Andriani

Background: Increased frequency of VDD/I has been found in warmer countries over the last years.Objective and hypotheses: To evaluate the response to vitamin D treatment in VDD/I among children and adolescents with type 1 diabetes.Method: Total 25OHvitamin D levels (VDL) were measured in 76 consecutive children and adolescents with type 1 diabetes (36 males, mean age (S.D.) 13.6 (5.09) years, median disease duration ...

hrp0084p3-820 | Endocrine Oncology | ESPE2015

AIP Polymorphism in Familiar Isolated Pituitary Adenomas: Case Report

Viale Maria Lorena , Hernandez Claudia L , Rampi Maria Gabriela , Serra Maria Pia , Figueroa Veronica , Day Patricia Fainstein , Brunetto Oscar H

Background: Familiar isolated pituitary adenomas (FIPA) encompasses the familiar occurrence of isolated pituitary adenomas outside the setting of syndromic conditions such as MEN1 and Carney’s complex, and comprise about 2–3% of pituitary adenomas. About 20% of FIPA have mutations in the aryl hydrocarbon receptor interacting protein gene (AIP), usually associated with a worse outcome.Objective and hypotheses: Evaluate the presence of AIP gene m...

hrp0095p1-403 | Adrenals and HPA Axis | ESPE2022

Outcomes of treatment in pediatric Cushing`s disease

Yanar Eda , Makazan Nadezhda , Kareva Maria

Objective: The first line of treatment for Cushing`s disease (CD) is transsphenoidal surgery (TSS), whose effectiveness range is from 70 to 90%. If surgical treatment is unsuccessful or recurrence appears, radiation treatment (RT) is the next therapeutic option, which effectiveness range is also 90%, but the hypopituitarism rate as side effect of treatment is higher.Aim: Analysis of recurrence rates of CD and side ...

hrp0095p1-104 | GH and IGFs | ESPE2022

SARS-CoV-2 pandemic and GH treatment: new strategies to abate the distance

Corsello Giovanni , Campa Luigi , Cristina Maggio Maria

SARS-CoV- 2 pandemic induced to develop new strategies to abate the distance between patients, families and paediatricians, especially in cases of patients who need long-term therapies. Furthermore, the need to minimize the inflow of children and adolescents affected by chronic diseases into the hospitals induced paediatric endocrinologists to limit visits and to consider a new setting to assist children in treatment with growth hormone (GH). Telemedicine and smart-working cou...

hrp0095p1-298 | GH and IGFs | ESPE2022

Use of PDE5 inhibitors as a potential treatment for isolated growth hormone deficiency caused by alternate splicing of GH1 gene.

Pandey Amit , Natalia Rojas Velazquez Maria

Mutations in the GH1 gene cause isolated growth hormone deficiency (IGHD) by affecting production, secretion, and stability of growth hormone as well as its binding to GHR. A smaller isoform of GH1 is inactive and is linked to IGHD. While studying the impact of small GH isoform, we noticed that cells with the short 17.5 kD version of GH looked different from the control cells. We found that the production of short GH isoform distorts the cell morphology, contributing to detrim...

hrp0092fc8.1 | Pituitary, Neuroendocrinology and Puberty Session 1 | ESPE2019

Hypothalamic AgRP Neurons Drive Endurance in Food-restricted Mice

Miletta Maria Consolata , Horvath Tamas L.

Diseases of food restriction, such as anorexia and bulimia nervosa, are psychiatric conditions with the highest mortality. It is not known how these disorders emerge and what determine mortality. Individuals with these disorders frequently engage in compulsive exercise. States of food restriction are associated with elevated activity of hypothalamic neurons that produce AgRP, which cells are crucial for feeding and can promote stereotypic behaviors.Here,...

hrp0092t5 | Top 20 Poster | ESPE2019

Evaluation of Toll-like Receptor 2 Expression on T Lymphocytes in Patients with Graves' Disease in Relation to the Clinical Parameters

Klatka Maria , Grywalska Ewelina , Polak Agnieszka

Introduction: Graves'disease (GD) is a polygenic and multifactorial disease.The innate immune system is a complex network of structured cells and proteins, including the Toll-like receptors (TLRs), which are also expressed on the cells of the adaptive immune system.The aim was to assess the relationship between the expression of TLR-2 on the surface of T CD4+ and CD8+ lymphocytes in pat...

hrp0092p2-163 | GH and IGFs | ESPE2019

Growth Response in Short Preterm- Born Children Small for Gestational Age in First Year of Growth Hormone Treatment

Korpal-Szczyrska Maria , Szczyrski Jan , Mysliwiec Malgorzata

Background: Growth hormone (rGH) treatment is an approved growth promoting therapy in children born small for gestational age (SGA) without spontaneous catch-up. SGA infants may be born either full-term or premature. Prematurity is an additional risk factor for adult short stature. Premature children born SGA may potentially be affected by combination of the effects of prematurity and SGA status. There are only few reports on premature SGA children treated wit...